- Home
- TDF vs DSGN Comparison
TDF vs DSGN Comparison
Compare TDF & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDF
- DSGN
- Stock Information
- Founded
- TDF 1994
- DSGN 2017
- Country
- TDF Singapore
- DSGN United States
- Employees
- TDF N/A
- DSGN N/A
- Industry
- TDF Finance/Investors Services
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- TDF Finance
- DSGN Health Care
- Exchange
- TDF Nasdaq
- DSGN Nasdaq
- Market Cap
- TDF 244.7M
- DSGN 224.8M
- IPO Year
- TDF N/A
- DSGN 2021
- Fundamental
- Price
- TDF $9.47
- DSGN $3.73
- Analyst Decision
- TDF
- DSGN Hold
- Analyst Count
- TDF 0
- DSGN 1
- Target Price
- TDF N/A
- DSGN $4.00
- AVG Volume (30 Days)
- TDF 79.2K
- DSGN 91.9K
- Earning Date
- TDF 01-01-0001
- DSGN 05-07-2025
- Dividend Yield
- TDF N/A
- DSGN N/A
- EPS Growth
- TDF N/A
- DSGN N/A
- EPS
- TDF N/A
- DSGN N/A
- Revenue
- TDF N/A
- DSGN N/A
- Revenue This Year
- TDF N/A
- DSGN N/A
- Revenue Next Year
- TDF N/A
- DSGN N/A
- P/E Ratio
- TDF N/A
- DSGN N/A
- Revenue Growth
- TDF N/A
- DSGN N/A
- 52 Week Low
- TDF $7.15
- DSGN $2.60
- 52 Week High
- TDF $10.62
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- TDF 48.70
- DSGN 48.52
- Support Level
- TDF $9.48
- DSGN $3.31
- Resistance Level
- TDF $9.70
- DSGN $4.13
- Average True Range (ATR)
- TDF 0.13
- DSGN 0.31
- MACD
- TDF -0.02
- DSGN 0.04
- Stochastic Oscillator
- TDF 6.67
- DSGN 61.27
About TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.